Related Experiment Videos
In vivo antisense imaging.
1INSERM U334 Service hospitalier Frédéric Joliot, CEA/DSV, Orsay, France. tavitian@shfj.cea.fr
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)
|December 6, 2000
Summary
Antisense oligonucleotides offer promising in vivo molecular imaging of gene expression. Further advancements in radiosynthesis, stability, and targeting are crucial for their application as nuclear medicine radiopharmaceuticals.
Area of Science:
- Biochemistry
- Molecular Biology
- Nuclear Medicine
Background:
- Antisense oligonucleotides are nucleic acid chains that bind to RNA via hybridization.
- In vitro, they are used to detect or block specific RNA sequences.
- In vivo applications for molecular imaging of gene expression are attractive but challenging.
Purpose of the Study:
- To review the current achievements and requirements for using antisense oligonucleotides as in vivo diagnostic agents in nuclear medicine.
- To highlight the necessary improvements in radiosynthesis, stability, targeting, and binding.
Main Methods:
- Review of existing literature on antisense oligonucleotide technology.
- Analysis of challenges and progress in adapting oligonucleotides for in vivo imaging.
- Examination of applications in nuclear medicine radiopharmaceuticals.
Main Results:
- Antisense oligonucleotides show potential for gene expression imaging.
- Significant improvements are needed in oligonucleotide radiosynthesis and stability.
- Targeting and specific/non-specific binding require further optimization for clinical use.
Conclusions:
- Antisense oligonucleotides are promising for molecular imaging but face technical hurdles.
- Progress in radiosynthesis, stability, and binding is essential for their clinical translation.
- Further research is needed to fully realize their potential as nuclear medicine radiopharmaceuticals.